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Abstract
Introduction: The incidence of vitamin D deficiency in critically ill patients has been reported to range from as
low as 17% to as high as 79%. Data regarding the relationship between 25-hydroxyvitamin D levels and outcomes
in the medical intensive care unit are sparse. The goal of the study was to evaluate the prevalence of 25-
hydroxyvitamin D deficiency in the medical intensive care unit and its relationship with outcomes.
Method: This was a retrospective study in a medical intensive care unit (MICU) at an inner city community
hospital. The study period was between October 2009 and February 2010.
Results: Of the 932 patients admitted during the study period, 25-hydroxyvitamin D vitamin D (25(OH)D) levels
were available in 523 (53%); 86 of them were excluded from the study due to readmission to the intensive care
unit. Deficiency was defined as 0 to 19.9 ng/dL 25(OH)D levels, insufficiency as 20 to 29.9 ng/dL, and normal levels
as ≥30 ng/dL. Of the 437 patients studied, 25(OH)D deficiency was identified in 340 (77.8%), insufficiency in 74
(16.9%), and normal levels in 23 (5.3%) patients. Patients with 25(OH)D deficiency/insufficiency were younger (P =
0.015), were male (P = 0.001), and had kidney disease (P = 0.017) and lower total serum calcium levels (P = 0.003).
Hospital mortality was higher in patients with 25(OH)D deficiency (P = 0.01). No differences in ventilator days or
length of stay in the MICU were evident among the three groups. Analysis by multiple logistic regression
demonstrated that acute physiology and chronic health evaluation (APACHE) IV score ((odds ratio (OR) 1.036; 95%
confidence interval (CI) 1.024-1.048, P < 0.0001), ventilator requirement (OR 7.7; 95% CI 4.3-13.98, P < 0.0001), 25
(OH) D levels(OR 0.942; 95% CI 0.942-0.904, P < 0.0005) and 25(OH) D deficiency (OR 8.7; 95% CI 1.03-72.8, P <
0.0469) showed statistical significance. There was no association between 25(OH)]D insufficiency and hospital
mortality. The mean 25(OH)D level of survivors (27.9 ± 9.7 ng/dL) was higher than for non-survivors (9.7 ± 4.7 ng/
dL; P < 0.0001).
Conclusions: The study results demonstrate an association between 25(OH)D deficiency and hospital mortality in
MICU patients. A randomized prospective study to evaluate the effect of vitamin D replacement therapy on
mortality is warranted.
Introduction
Vitamin D is a fat-soluble vitamin that regulates calcium
metabolism. Adequate levels of 25(OH)D, the storage
form of vitamin D, are dependent on cutaneous synth-
esis stimulated by ultraviolet radiation and/or adequate
dietary intake of fortified foods and nutritional supple-
ments. A deficiency in 25(OH)D is estimated to exist in
50% to 60% of the older population in North America
and worldwide [1]. Recent evidence suggests that the
role of vitamin D is broader than the regulation of cal-
cium metabolism. Vitamin D has been shown to have
anti-inflammatory and anti-proliferative properties, and
its deficiency has been linked to all-cause mortality and
cardiovascular disease and cancer [2-5]. The incidence
of 25(OH)D deficiency in critically ill patients has been
reported to range from as low as 17% to 79% [6-8]. Data
regarding the relationship between 25(OH)D levels and
outcome in the medical intensive care unit (MICU) are
sparse with new reports suggesting the relationship of
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the critically ill [6-9].
Most experts agree that levels less than 20 ng/dL 25
(OH)D are considered deficient and levels between 20
to 30 ng/dL are insufficient [10-12].
The goal of the study was to evaluate the prevalence
o f2 5 ( O H ) Dd e f i c i e n c yi na ni n n e r - c i t yM I C U .T h ep r i -
mary outcome was hospital mortality, and secondary
outcomes included duration of mechanical ventilation
and MICU length of stay. A subgroup analysis for pri-
mary and secondary outcomes was performed for
patients admitted from skilled nursing facilities.
Materials and methods
Study design and setting
This was a retrospective study of all patients admitted to
the MICU between October 2009 and February 2010 at
a 26-bed closed unit. Our MICU is a university-affiliated
inner-city hospital staffed daily by two pulmonary and
critical care-trained attending physicians, a pulmonary
fellow, and internal medicine residents.
Methods
All patients admitted to the MICU who had levels of 25
(OH)D available were included in the study. Patients
readmitted to MICU during the same period of hospita-
lization were excluded, those patients either already had
25(OH)D levels available from the first MICU admission
and repeated levels were not performed within 24 hours
of MICU readmission or did not any level available. The
data were collected as part of a performance improve-
ment project looking to the prevalence of 25(OH)D defi-
ciency in our MICU. 25(OH)D levels were collected
randomly during the first 24 hours of admission to the
intensive care unit. There were no strict criteria to
obtain 25(OH)D levels. The physicians received educa-
tion regarding the high prevalence of hypovitaminosis in
our community and were encouraged to evaluate for
hypovitaminosis when patients were admitted to the
hospital. Baseline demographics (age, gender, and race),
history of end stage renal disease (ESRD) or chronic kid-
ney disease (CKD), as well as acute physiology and
chronic health evaluation (APACHE) IV were collected.
The APACHE derived risk of death during hospitaliza-
tion was determined from the worst values obtained
within 24 hours of MICU admission. Clinical and
laboratory variables obtained during the first 24 hours
of hospital admission included serum levels of total cal-
cium, phosphate, creatinine, glucose, albumin and 25
(OH)D. Utilization and duration of invasive mechanical
ventilation, ICU length of stay (LOS), and hospital mor-
tality were analyzed. Length of stay in the MICU was
defined as the time from ICU admission to time of
transfer out of the MICU. This study was approved by
the hospital institutional research review board, and the
need for informed consent was waived.
Serum 25(OH)D concentrations were assayed by
liquid chromatography-tandem mass spectrometry at
Quest Diagnostics, New York, NY. The analytical sensi-
tivity is 4 ng/mL for 25OHD2 and 25OHD3 with a
reportable range of 4 to 512 ng/mL for 25OHD2 and
25OHD3
Definition of Vitamin D deficiency
There is no firm consensus regarding optimal levels of
25(OH)D. According to the workshop consensus confer-
ence for vitamin D nutritional guidelines and a study
that investigated the potential beneficial effects of vita-
min D for multiple health outcomes, the minimum
desirable serum level of 25(OH)D is suggested to be 20
to 30 ng/dL [1,10,12]. Studies examining 25(OH)D defi-
ciency in intensive care units have no agreement on the
cutoff levels for critically ill patients, with deficiency
being defined as 25(OH)D levels of less than 15 ng/dL
to less than 29 ng/dL [8,9,13]. In our study, we used a
25(OH)D cutoff level of less than 19.9 ng/dL to define
25(OH)D deficiency. 25(OH)D insufficiency was defined
as 20 to 29.9 ng/dL [11,14,15].
Definition of renal failure
There is no consensus on the amount of dysfunction
that defines acute kidney injury, with more than 30 defi-
nitions in use today [16]. Acute renal failure was defined
as a serum creatinine × >1.5 and acute or chronic renal
failure as a worsening of renal function in a patient with
chronic kidney disease (serum creatinine × 3). End-stage
renal disease (ESRD) was defined as any patient with
chronic kidney disease on long term hemodialysis [17].
Statistical analysis
Data analysis was conducted using the SPSS v15.0. Dis-
crete variables are expressed as counts (percentage) and
continuous variables as means ± standard deviations
(SD). For the demographic and clinical characteristics of
the patients, differences between groups were assessed
using the chi-squared test and Fisher’se x a c tt e s tf o r
categorical variables and the Student’s t-test or Mann-
Whitney U test for continuous variables. A one-way
analysis of variance (ANOVA) was performed to explore
the impact of admitting diagnosis which were classified
in nine different categories: (a) Cardiac, (b) Gastrointest-
inal, (c) Metabolic, (d) Neurologic, (e) Obstructive Air-
way Disease, (f) others, (g) Pulmonary, (h) Renal, and (i)
Sepsis, on the continuous dependent variable outcome
of log-Vitamin D levels. A multiple logistic regression
model was performed for the whole population, with
mortality as the dependent variable, and age, gender,
APACHE IV score, ventilator requirement, acute/acute
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calcium, phosphate, creatinine, and 25(OH)D deficiency
and insufficiency as independent variables. Additionally,
logistic regression with a dependent variable of mortality
was performed with a total of 10 independent continu-
ous variables; (a) APACHE, (b) age, (c) 25(OH)D levels,
(d) ventilator days, (e) ICU length of stay, (f) total cal-
cium, (g) phosphate, (h) serum creatinine, (i) serum
albumin, and (j) serum glucose. A P value less than 0.05
was considered statistically significant. To evaluate the
prognostic utility of 25(OH)D levels, a receiver-operat-
ing characteristic (ROC) curve was constructed.
Results
A total of 932 patients were admitted to the MICU
during the 4-month study period. 25(OH)D levels were
a v a i l a b l ef o r5 2 3( 5 6 % )p a t i e n t s ;o ft h e s e ,8 6p a t i e n t s
were excluded due to readmission to the MICU during
the same hospitalization. Of the 437 patients studied,
25(OH)D deficiency was identified in 340 (77.8%)
patients, insufficiency in 74 (16.9%) patients, and nor-
mal levels in 23 (5.3%) patients (Figure 1). Characteris-
tics of the patients were stratified according to 25
(OH)D levels on admission (Table 1). Patients with 25
(OH)D deficiency/insufficiency were more likely to be
younger (P = 0.015), to be male (P = 0.001), to have
acute/acute on CKD (P = 0.017), and to have lower
total serum calcium levels (P = 0.003). A comparison
among the three 25(OH)D groups by admission diag-
n o s i si ss h o w ni nT a b l e2 .T h e r ew e r en od i f f e r e n c e s
in the mean log-25(OH)D levels among the nine cate-
gories for admitting diagnosis. (P = .099). Comparison
of 25-hydroxyvitamin D levels among different admis-
sion diagnosis groups did not show statistical signifi-
cance (Table 3).
Comparisons of primary and secondary outcomes are
shown in Table 4.
Primary Outcome
Hospital mortality was higher in patients with 25(OH)D
deficiency (P = 0.01). Comparisons of observed versus
APACHE IV-predicted mortality revealed that the
observed mortality was higher than the predicted mor-
tality among patients with 25(OH)D deficiency (24.1%
versus 8.6%) and 25(OH)D insufficiency (12.2% versus
7%). However, in patients with normal levels of 25(OH)
D, the observed mortality was lower than predicted
(4.4% versus 8%).
932
Total MICU admissions
523
25 (OH)D available
409
25 (OH)D not available
86
Excluded due to 
readmission
437
included
74
Insufficiency 25 (OH)D
23
Normal 25 (OH)D
340
Deficiency 25 (OH)D 
Figure 1 Flowchart of patients in the cohort.
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Page 3 of 9Early (≤2 days) versus late mortality is shown in Table 5.
Classification percentages were similar between the mortal-
ity and 25(OH)D groups, but a higher percentage of cases
with insufficient 25(OH)D experienced early mortality
(13.8%) than late mortality (7.9%). A higher percentage of
cases with deficient 25(OH)D levels were classified as late
mortality (69.5%) versus early mortality (30.5%) (P < 0.0005)
Unadjusted and adjusted odds ratios (ORs) for mortal-
ity are shown in Table 6. The following variables
demonstrated statistical significance after adjustment by
multiple logistic regression analysis: APACHE IV score
(OR 1.036; 95% confidence interval (CI) 1.024-1.048, P <
0.0001), ventilator requirement (OR 7.7; 95% CI 4.3-
13.98, P < 0.0001), and 25(OH)D deficiency (OR 8.7;
95% CI 1.03-72.8, P < 0.0469). No association between
25(OH)D insufficiency and hospital mortality (OR 4.3;
95% CI 0.4-40.9, P = 0.2081) was evident.
Logistic regression with a dependent variable of mor-
tality and continuous variables was performed for
greater retention of information during analysis (Table
7). Wald statistics indicated that four variables contribu-
ted significantly to the model: APACHE (c2=2 9 . 0 1 ,
OR 1.037; 95% CI 1.023-1.050, P < .0005), 25(OH) D
levels (c2 = 8.083, OR 0.94; 95% CI 0.904-0.982, P =
0.004), admission albumin levels (c2 = 13.27, OR 0.457;
95% CI 0.0.300-1.091, P < 0.0005), and ventilator days
(c2 = 9.2, OR 1.15; 95% CI 1.054-1.272, P = 0.002).
The mean 25(OH)D level for survivors (27.9 ± 9.7 ng/
dL) was higher than for non-survivors (9.7 ± 4.7 ng/dL;
P < 0.0001). The ROC curve for 25(OH)D levels is
s h o w ni nF i g u r e2 ,a n dt h e2 5 ( O H ) Di n t e r s e c t i o nc u r v e
is shown in Figure 3. The area under the curve (AUC)
was 0.66, and the cut-off value that maximizes sensitiv-
ity at 59.8% and specificity at 58% is a 25(OH)D level of
10 ng/dL. Sensitivity and specificity crossed at a prob-
ability level of 0.235 for the aforementioned 25(OH)D
l e v e l .W i t hap r e v a l e n c er a t eo f7 7 . 8 % ,t h ep o s i t i v ep r e -
dictive value (PPV) for mortality with a 25(OH)D level
less than 10 ng/dL was 83.64% and the negative predic-
tive value (NPV) was 29.52%..
Secondary Outcomes
Factors that did not significantly differ between stratified
groups were latitude, ventilator days and MICU length
of stay. The mean latitude for our study group was 40°
north (SD 0.5° north). There was no difference in venti-
l a t o rd a y so rM I C UL O Sf o rt h ed i f f e r e n ta d m i t t i n g
diagnosis groups.
Comparison of patients with available 25(OH)D levels
versus patients without 25(OH)D revealed no difference
Table 1 Clinical characteristics of patients with available 25-hydroxyvitamin D levels
Variable 25(OH)D Deficiency
≤19.9 ng/dL
N = 340
25(OH)D Insufficiency
20-29.9 ng/dL
N=7 4
25(OH)D Normal
≥30 ng/dL
N=2 3
P
Age (years) 55.6 ± 16.5 58.6 ± 19.2 65.4 ± 16.6 0.015
Gender - Male (%) 176 (51.8%) 28 (37.9%) 4 (17.4%) 0.001
APACHE IV 68.3 ± 28.1 60.9 ± 25.9 67.2 ± 20.9 0.11
Ventilator requirement 123 (36.2%) 23 (31%) 7 (30.4%) 0.63
Acute/acute on chronic renal failure 92 (27%) 11 (14.9%) 2 (8.7%) 0.017
ESRD on hemodialysis 21 (7.1%) 6 (8.1%) 2 (8.7%) 0.92
Total calcium serum (mg/dL) 8.6 ± 1.1 9.0 ± 1.1 9.4 ± 1.3 0.0003
Phosphate serum (mg/dL) 3.7 ± 1.7 4.1 ± 5.7 3.3 ± 1.2 0.34
APACHE IV, acute physiology and chronic health evaluation; ESRD, end-stage renal disease; N, Number; 25(OH)D, 25-hydroxyvitamin D
Table 2 Comparison of admission diagnosis groups based on deficient, insufficient, and normal 25-hydroxyvitamin D
levels
Variable 25(OH)D Deficiency ≤ 0-19.9 ng/dL
N (%) = 340
25(OH)D Insufficiency 20-29.9 ng/dL
N (%) = 74
25(OH)D Normal ≥30 ng/dL
N (%) = 23
Total
N (%)
Cardiac 14(4%) 5(6.7%) 2(8.6%) 21(4.8%)
Gastrointestinal 39(11.4%) 5(6.7%) 3(13%) 47(10.7%)
Metabolic 39(11.4%) 8(10.8%) 3(13%) 50(11.4%)
Neurological 46(13.5%) 6(8.1%) 3(13%) 55(12.5%)
Obstructive airway disease 42(12.3%) 17(22.9%) 1(4.3%) 60(13.7%)
Pulmonary 64(18.8%) 13(17.5%) 3(13%) 80(18.3%)
Others 34(10%) 10(13.5%) 4(17.3%) 48(10.9%)
Renal 19(5.5%) 3(4%) 0(0%) 22(5%)
Sepsis/Septic shock 43(12.6%) 7(9.4%) 4(17.3%) 54(12.3%)
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ment or mortality (Figure 4).
Discussion
Our results demonstrate that 56% of patients admitted
to our MICU have a 25(OH)D deficiency. This inci-
dence is higher than other large studies showing a pre-
valence between 20% to 40% [6,8,9]. Inner-city hospitals
a r eu n i q u ei nt h es e n s et h a tt h e yc a r ef o ra nu n d e r -
served population with a higher rate of unemployment,
lower income, higher use of toxic substances and, in
general, less than optimum medical care; all of which
lead to an increased incidence of uncontrolled diseases
and a higher risk for hypovitaminosis.
We found an association between 25(OH)D deficiency
and hospital mortality in our MICU population. 25(OH)
D levels were significantly higher in survivors than in
non-survivors. In our study, total serum hypocalcemia
was not associated with an increased hospital mortality,
although levels of ionized calcium, 25(OH)D3 and PTH
were not studied. Our data are in line with another
study showing a correlation between serum levels of
albumin and mortality [5]. Several explanations are pos-
sible for the association between 25(OH)D deficiency
and hospital mortality. The vitamin D receptor is
expressed in nearly all cells in the body, and the activat-
ing enzyme 1-alpha-hydroxylase is expressed in many
tissue types. Laboratory, cell culture, and animal studies
suggest that vitamin D may lower cancer risk by inhibit-
ing cell proliferation, angiogenesis, metastasis, and
inflammation, as well as inducing apoptosis and cellular
differentiation. Several of these mechanisms are relevant
to atherosclerosis and cardiovascular disease, as well as
sepsis, respiratory failure, and other diseases commonly
seen in the critically ill [12,18-20]. Deficiency of 25(OH)
D has been implicated as a cause of increased cardiovas-
cular events and death [21-24]. The increased mortality
in the critically ill with vitamin D deficiency might be
due to changes in glucose and calcium metabolism, and/
or immune and endothelial cell dysfunction due to the
deficiency [25-29].
Endothelial cell dysfunction has been proposed as a
potential cause of multiple organ dysfunction syndrome
[30-32]. It is possible that 25(OH)D deficiency amplifies
the metabolic derangements and impaired immune reg-
ulation seen in critically ill states, which may lead to
worse outcomes than would be experienced with normal
vitamin D levels. Furthermore, 25(OH)D deficiency has
been implicated in sepsis, stroke, inflammatory bowel
disease, autoimmune conditions and asthma [33-39].
Contrary to the study by McKinney et al., we did not
find a correlation between 25(OH)D deficiency and an
increased length of stay among patients admitted to the
MICU; it is important to note that in their study the
LOS was dichotomized to a LOS less and more than
three days, respectively [8].
Risk factors for low vitamin D levels include older age,
living in northern latitudes, sun avoidance, dark skin
pigmentation, obesity, low dietary intake of vitamin D,
and various medical conditions, especially malabsorption
syndromes. These factors are especially important for
older patients in nursing home facilities [40].
Causes of low 25(OH)D levels in patients admitted to
ICUs are multifactorial. In addition to the well-known
etiologies, it is important to consider other factors such
as interaction with medications, abnormal gastrointest-
inal function and the effect of fluid resuscitation [41].
Contrary to our expectations and reports in the litera-
ture, our study showed that patients with either 25(OH)
Table 3 Comparison of 25-hydroxyvitamin D levels
between admission diagnosis groups*
Admission Diagnosis groups Mean 25-hydroxyvitamin D
(ng/dL) ± SD (range)
Cardiac disorders. N (%) 15.1 ± 11.1 (4-43)
Gastrointestinal disorders. N (%) 12.5 ± 10.1 (4-50)
Metabolic disorders. N (%) 13.9 ± 8.9 (4-40)
Neurological disorders. N (%) 12.0 ± 9.5 (4-51)
Obstructive airway disease. N (%) 15.7 ± 10.6 (4-74)
Pulmonary disorders. N (%) 13.1 ± 8.4 (4-42)
Others. N (%) 16.6 ± 11.7 (4-73)
Renal disorders. N (%) 12.2 ± 6.5 (4-26)
Sepsis/Septic shock. N (%) 13.3 ± 9.2 (4-42)
* No statistical significance was reached between the groups
Table 4 Comparison of outcomes based on deficient, insufficient, and normal 25-hydroxyvitamin D levels.
Variable 25(OH)D Deficiency
≤0-19.9 ng/dL
N = 340
25(OH)D Insufficiency
20-29.9 ng/dL
N=7 4
25(OH)D Normal
≥30 ng/dL
N=2 3
P
Actual Hospital Mortality 82 (24.1%) 9 (12.2%) 1 (4.4%) 0.01
Predicted ICU mortality [APACHE IV] 8.6% 7% 8%
Days on a ventilator 6.9 ± 6.0 5.9 ± 6.0 6.4 ± 5.1 0.77
ICU length of stay [days] 4.3 ± 4.5 3.7 ± 3.9 4.2 ± 3.7 0.54
APACHE IV, acute physiology and chronic health evaluation; N, number; 25(OH)D, 25-hydroxyvitamin D.
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than patients with normal 25(OH)D levels and they
were predominantly of male gender. The association
between 25(OH)D levels and hospital mortality in men
and in younger patients is unclear. Most published stu-
dies show a higher prevalence of vitamin D deficiency in
women and the elderly [9,42,43]. The large multicenter
s t u d yd o n eb yB r a u net al. confirmed our association
between low 25(OH)D levels and younger age, but not
with male gender [9]. These findings could be just a
reflection of the general vitamin deficiency in our
population.
In our cohort, 93% of patients with ESRD and 98% of
patients with acute and acute on CKD had 25(OH)D
deficiency/insufficiency, and these findings are consis-
tent with other published findings [14,44-49]. Chronic
kidney disease is characterized by decreased renal phos-
phate excretion, with resultant increases in serum phos-
phate levels; furthermore, there is decreased conversion
of vitamin D to its active form, 1,25-dihydroxyvitamin
D3 (1,25(OH)D3), resulting in decreased levels of circu-
lating 1,25(OH)D3 and serum calcium and decreased
intestinal calcium absorption. The hyperphosphatemia,
hypocalcemia, and decreased levels of active vitamin D
result in increased synthesis and secretion of parathyroid
hormone. Some studies found no interaction between
low levels of 25(OH)D and PTH concentrations or cal-
cium levels. This could suggest that the association of
25(OH)D status and mortality is not significantly
modified by PTH or calcium levels [6,47,50]. Vitamin D
deficiency has been associated with cardiovascular mor-
tality and all-cause mortality in patients with CKD
[44-47,50-52]. There is no conclusive data regarding
vitamin D supplementation and decrease in mortality or
other outcomes in critically ill patients. A meta-analysis
of randomized controlled trials suggested that supple-
mentation of 400 to 830 IU of vitamin D decreased
mortality in the general population during the trial peri-
ods [21]. In a subsequent study, there was no associa-
tion between vitamin D classes and mortality [6]. Levels
of 25(OH)D ≥150 ng/dL are potentially harmful and are
associated with elevated risk of hypercalcemia, vascular
soft tissue calcification, and hyperphosphatemia [53].
Vitamin D intoxication can potentially be life-threaten-
ing but the majority of officially recorded cases could be
related to prolonged intakes of >40,000 IU per day [54].
One small study looking at the short-term metabolic
effect of high dose oral vitamin D3 replacement in the
intensive care unit did not reveal any complications
[55]. A recent Cochrane review of fifty randomized trials
with 94,148 participants showed that vitamin D in the
form of vitamin D3 seems to decrease mortality in pre-
dominantly elderly women [56].
Our work has several potential limitations. First, this
was a retrospective single center study and we did not
sample 25(OH)D levels sequentially. The 25(OH)D
levels obtained on admission are probably a reflection of
pre-admission deficiency. Vitamin D levels were not
Table 5 Contingency table of cross tabulations between classifications of Vitamin D levels and stages of mortality
(N = 92)
25(OH)D Deficiency ≤ 0-19.9 ng/dL
N=8 2
25(OH)D Insufficiency 20-29.9 ng/dL
N=9
25(OH)D Normal ≥30 ng/dL
N=1
Total
Early Mortality (frequency) 25 4 0 29
% within mortality category 86.2 13.8 0.0 100.0
% within Vitamin D category 30.5 44.4 0.0 31.5
% of total 27.2 4.3 0.0 31.5
Late Mortality (frequency) 57 5 1 63
% within mortality category 90.5 7.9 1.6 100.0
% within Vitamin D category 69.5 55.6 100.0 68.5
% of total 62.0 5.4 1.1 68.5
N, number
Table 6 Logistic regression analysis for mortality risk using categorical variables
Variable Unadjusted OR for Death P Adjusted OR for Death 95% CI P
Ventilator requirement 11.7 <0.0001 7.7 4.3-13.98 <0.0001
25(OH)D deficiency 6.99 0.0289 8.7 1.03-72.8 0.0469
25(OH)D insufficiency 3.05 0.29 4.3 0.4-40.9 0.2081
APACHE IV, acute physiology and chronic health evaluation; CI, confidence interval; 25(OH)D, 25-hydroxyvitamin D; OR, odds ratio.
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of the groups with and without available vitamin D
levels reflected no gross bias. Second, the study was
completed in the fall and winter months, which have
been traditionally associated with lower levels of vitamin
D, and may have overestimated the deficiency of vitamin
D in our population. Third, our study was conducted in
a MICU and cannot be generalized to cardiac, surgical,
or cardiothoracic units. Fourth, our study did not intend
to evaluate the association of low 25(OH)D levels and
inflammatory markers or incidence of infectious dis-
eases, neither did we attempt to see the effect of 25
(OH)D replacement on mortality. Finally, PTH and
1,25D3 levels were not available and we cannot exclude
the confounding effects of these variables.
Conclusions
In conclusion, we report on a large cohort of patients
with 25(OH)D deficiency and insufficiency in a MICU
setting. Our study shows a clear association between
25(OH)D levels and hospital mortality in critically ill
patients. 25(OH)D levels of 10 ng/dL predicted hospi-
tal mortality in 83.6% of this cohort. The observed
hospital mortality for 25(OH)D deficient patients was
higher than the predicted mortality based on admission
APACHE IV score.
The finding that 25(OH)D deficiency, especially at
levels less than 10 ng/dL, is associated with increased
hospital mortality has both clinical and research implica-
tions. Clinically, patients admitted to the medical ICU
who present with a 25(OH)D deficiency are at greater
risk for short-term hospital mortality and may therefore
potentially benefit from more intensive surveillance at
ICU admission. Future studies are needed to answer
some of the most relevant questions such as: Is 25(OH)
D deficiency merely another marker for severity of ill-
ness? Can hospital mortality, risk of infections, LOS in
the intensive care unit be changed or modulated just by
evaluating and correcting 25(OH)D deficiency ? What
are the optimal doses for replacement and what is the
long term outcome in those patients? Future research is
warranted to determine whether correction of 25(OH)D
deficiency is associated with improved outcomes for
ICU patients.
Key Messages
￿ 25(OH)D deficiency and insufficiency is a common
finding in a medical intensive care unit.
￿ 25(OH)D deficiency in the intensive care unit is
associated with increased risk for hospital mortality.
￿ There was correlation between 25(OH)D deficiency
and late mortality (≥2 days) whereas this effect was
not seen in 25(OH)D insufficiency.
￿ A 25(OH)D level less than 10 ng/dL had a positive
predictive value for hospital mortality of 83.6%.
￿ Measurement of 25(OH)D D levels should be con-
sidered as part of the routine initial laboratory tests
obtained in the medical intensive care unit.
Table 7 Logistic regression analysis for mortality risk
using continuous variables
Variable Wald c
2 P-value OR 95% CI
APACHE 29.013 <.0005 1.037 1.023-1.050
25(OH)D 8.083 .004 0.942 0.904-0.982
Ventilator days 9.285 .002 1.158 1.054-1.272
Albumin 13.276 <.0005 0.457 0.300-1.091
Age 0.432 .511 1.007 0.987-1.027
ICU LOS 0.015 .903 1.007 0.906-1.118
Total calcium 0.082 .775 0.963 0.745-1.245
Phosphate 0.047 .828 1.012 0.910-1.125
Creatinine 0.580 .446 0.946 0.821-1.125
Glucose 1.778 .182 0.999 0.997-0.696
APACHE IV, acute physiology and chronic health evaluation; CI, confidence
interval; 25(OH)D, 25-hydroxyvitamin D; LOS, Length of stay; OR, odds ratio.
Figure 2 Vitamin D receiver operating curve.V i t a m i nDr e c e i v e r
operating characteristic curve revealing an area under the curve of
0.66.
Figure 3 Vitamin D intersection curve. Vitamin D intersection
curve revealing sensitivity at 59.8% and specificity at 58% for a
vitamin D level of 10 ng/dL.
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